Takeaway
Clinical trial participation is not associated with overall survival (OS) in patients with high-risk neuroblastoma but is associated with improved OS in intermediate-risk patients, and there is no evidence of racial or ethnic enrollment bias in these clinical trials.
Why this matters
Previous evidence has shown that people enrolled in clinical trials may experience benefits associated with strict adherence to standard of care, even if not receiving study drug. This study demonstrates that enrollment in clinical trials should continue to be encouraged.